Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose (OTC:RDTCF) announced it will satisfy accrued interest on its secured convertible notes by issuing common shares. The Company expects to issue 592,533 Common Shares no later than October 15, 2025 at a deemed issue price of $0.16 per share, covering $94,806.23 of accrued interest payable as of September 30, 2025.
The Notes were issued across four tranches in 2023 as part of a private unit financing totaling $3,134,445 principal and 15,672,225 warrants. The Notes mature on November 30, 2025 and bear interest at 12.0% per annum, with interest payable quarterly in Common Shares based on the CSE closing price on the last trading day of each quarter. All issued shares will be subject to a four‑month plus one day hold period.
Rapid Dose Therapeutics (CSE: DOSE) has submitted its QuickStrip™ Nicotine products for Health Canada approval in multiple dosage formats (1mg, 2mg, 3mg, and 4mg). The product is an innovative oral thin film technology that delivers nicotine through the oral mucosa as a safer alternative to smoking.
The company is currently conducting a pharmacokinetic (PK) clinical trial comparing QuickStrip™ Nicotine to traditional cigarettes. RDT has collaborated with a leading global cigarette manufacturer over the past 30 months and filed two PCT patent applications with partner Aavishkar.
The Canadian nicotine pouches market, valued at $112.2 million in 2024, is projected to grow at 4.7% annually through 2030. This submission follows a previous 2019 application that was interrupted by COVID-19.
Rapid Dose Therapeutics (CSE: DOSE) and Eco Canadian Organic Inc. have launched a Health Canada-funded Substance Use and Addictions Program (SUAP) Harm Reduction Pilot Project targeting the opioid crisis in First Nations communities. The two-year initiative introduces Replace+, a sublingual cannabis strip developed using RDT's QuickStrip™ technology.
The project aims to provide an alternative delivery method for managing opioid withdrawal symptoms and reducing dependency. The collaboration focuses on developing culturally appropriate solutions for Indigenous communities, which are disproportionately affected by the opioid crisis. The initiative represents a significant step in RDT's strategy to provide healthcare solutions for vulnerable populations.
Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction to settle director fees. The company will issue common shares to its five non-management directors to cancel $100,000 in total fees owed for the fiscal quarters ended February 28, 2025, and May 31, 2025.
The shares will be issued at a deemed price of $0.21 per share, based on the closing price on June 27, 2025. The transaction, expected to complete by July 15, 2025, aims to improve the company's financial position by reducing liabilities. The issued shares will be subject to a four-month hold period.
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due June 30, 2025, on its secured convertible notes. The company will issue 506,878 common shares at $0.185 per share to settle $93,775.72 in accrued interest.
The notes, issued in 2023 through a private placement financing totaling $3,134,445, bear interest at 12.0% per annum and mature on November 30, 2025. The original financing units included both notes and warrants, with 15,672,225 warrants issued in total. The interest payment shares will be subject to a four-month hold period.
Rapid Dose Therapeutics (RDTCF) has announced plans for an equity private placement financing to raise up to $3 million in gross proceeds. The financing will offer up to 13,636,364 units at $0.22 per unit, with each unit comprising one common share and one warrant. The warrants will be exercisable at $0.34 per share for a two-year term.
Meadowbank Asset Management will serve as the agent, receiving a 6% cash commission and 6% in agent warrants from investors they introduce. The proceeds will be used for research and development, capital expansion, and working capital. The securities will have a four-month hold period from closing.
["Potential to raise up to $3 million in additional capital", "Proceeds will support R&D, capital expansion, and working capital needs", "Two-year warrant term provides flexibility for investors"]Rapid Dose Therapeutics (RDTCF) and Aavishkar Oral Strips have filed two crucial patent applications for innovative nicotine delivery technology. The patents cover both dissolvable and non-dissolvable oral nicotine strips using RDT's QuickStrip™ platform. The dissolvable variant enables nicotine delivery in under 2 minutes, while the non-dissolvable version offers extended release in a slim format.
The international PCT applications filed with WIPO extend protection to 158 jurisdictions worldwide. This development follows a pre-commercialization agreement with a leading global tobacco company announced in January 2025. The technology aims to provide a safer alternative for the 1.3 billion global tobacco users, targeting the 60% of smokers wanting to quit.
Rapid Dose Therapeutics (RDTCF) has announced a debt settlement agreement with certain creditors. The company plans to issue up to 2.5 million common shares in exchange for canceling approximately $500,000 in outstanding accounts payable. The Settlement Shares will be issued at $0.20 per share.
The transaction aims to improve RDT's financial position by reducing existing liabilities. Settlement Shares issued to Canadian residents will have a four-month hold period. The agreement requires Canadian Securities Exchange approval and will not create a new control person of the company.
Rapid Dose Therapeutics (RDTCF) has provided an update on its collaboration with the University of Regina's Faculty of Kinesiology & Health Studies for an NFL-funded medical cannabis research project. The study focuses on examining cannabinoids' effects on sport concussion and pain management.
The project has entered the clinical trial phase, investigating the bioavailability of CBD through RDT's QuickStrip™ sublingual delivery system compared to standard oral formulation. The randomized, two-arm clinical study, approved by Health Canada, involves researchers from the Universities of Regina, Saskatchewan, and British Columbia.
The study specifically examines the pharmacokinetic parameters of non-psychoactive cannabidiol (CBD) and its metabolites in healthy young adults. The QuickStrip™ technology consists of rectangular oral thin films infused with cannabis extract that dissolve under the tongue, releasing the compound directly into the mucus membranes.